0001193125-26-256013.txt : 20260603 0001193125-26-256013.hdr.sgml : 20260603 20260603192053 ACCESSION NUMBER: 0001193125-26-256013 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20260601 FILED AS OF DATE: 20260603 DATE AS OF CHANGE: 20260603 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Maduck Sean CENTRAL INDEX KEY: 0001698310 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-50679 FILM NUMBER: 261062719 MAIL ADDRESS: STREET 1: C/O CORCEPT THERAPEUTICS INCORPORATED STREET 2: 149 COMMONWEALTH DRIVE CITY: MENLO PARK STATE: CA ZIP: 94025 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: CORCEPT THERAPEUTICS INC CENTRAL INDEX KEY: 0001088856 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences EIN: 770487658 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 101 REDWOOD SHORES PARKWAY CITY: REDWOOD CITY STATE: CA ZIP: 94065 BUSINESS PHONE: 650.688.8803 MAIL ADDRESS: STREET 1: 101 REDWOOD SHORES PARKWAY CITY: REDWOOD CITY STATE: CA ZIP: 94065 4 1 ownership.xml 4 X0609 4 2026-06-01 0001088856 CORCEPT THERAPEUTICS INC CORT 0001698310 Maduck Sean false C/O CORCEPT THERAPEUTICS INCORPORATED 101 REDWOOD SHORES PARKWAY REDWOOD CITY CA 94065 false true false false See Remarks true Common Stock 2026-06-01 4 M false 25000 8.27 A 33977 D Common Stock 2026-06-01 4 S false 21069 70.1068 D 12908 D Common Stock 2026-06-01 4 S false 3931 70.7462 D 8977 D Common Stock 2026-06-01 4 A false 615 70.44 A 9592 D Common Stock 2026-06-01 4 A false 615 0.00 A 10207 D Common Stock 2026-06-02 4 F false 452 70.44 D 9755 D Common Stock 5147 I See Footnote Common Stock 20570 I See Footnote Common Stock 40000 I See Footnote Common Stock 34000 I See Footnote Common Stock 10000 I See Footnote Stock option (right to buy) 8.27 2026-06-01 4 M false 25000 0.00 D 2027-02-10 Common Stock 25000 141986 D Includes 888 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 2, 2025, 228 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 2, 2025, 205 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025 and 454 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer March 2, 2026. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. This transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person on December 8, 2025 in effect at the time of this transaction. Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $69.49 to $70.48 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request. Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $70.49 to $70.95 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request. The Reporting Person purchased shares ("Purchase Plan Shares") of the Issuer's common stock pursuant to a purchase plan ("Purchase Plan") established under the Corcept Therapeutics Incorporated 2024 Incentive Award Plan on June 1, 2026. In accordance with the Purchase Plan, the price was established based on the closing price on the day of the purchase. Shares underlie unvested restricted stock awards granted to the Reporting Person by the Issuer under the Purchase Plan. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person remains the beneficial owner of the Purchase Plan Shares through such one-year anniversary. These shares were withheld by the Issuer in order to satisfy certain tax withholding obligations in connection with the issuance of shares upon the vesting of restricted stock units. The closing price on June 1, 2026 was used to calculate the withholding obligation. Includes 228 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 2, 2025, 205 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025 and 454 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer March 2, 2026. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Represents the shares held by Sean and Molly Maduck Living Trust of which the Reporting Person is a co-trustee. Represents the shares held by MMM 2025, LLC of which the Reporting Person is a member and manager. Represents the shares held by SNM 2025 Grantor Retained Annuity Trust of which the Reporting Person is the trustee. Represents the shares held by SNM 2026 Grantor Retained Annuity Trust of which the Reporting Person is the trustee. Represents the shares held by Duckhill Capital, LLC of which the Reporting Person is President and disclaims beneficial ownership of the shares except to the extent of his pecuniary interest therein. Fully exercisable. President, Corcept Endocrinology The power of attorney under which this form was signed is on file with the Commission. /s/ Joseph Douglas Lyon, as attorney-in-fact for Sean Maduck 2026-06-03